InvestorWire NewsRoom

Article

Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate
August 22, 2022

Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate

  • Odyssey Health is a medical company focused on developing unique, life-saving medical products that offer clinical advantages for unmet clinical needs
  • Recently, the company reported positive results from Cohort I of its Multi-Day Ascending Dosing (“MAD”) portion of its Phase I clinical trial, coming weeks after the successful completion of Phase I Single Ascending Dosing (“SAD”) clinical trial
  • The MAD arm thus far shows that the drug is safe and well tolerated
  • Odyssey expects to report additional MAD results as they become available

A few weeks after completing its Phase I Single Ascending Dosing (“SAD”) clinical trial, Odyssey Health (OTC: ODYY) recently announced positive results from Cohort I of its Multi-Day Ascending Dosing (“MAD”) portion for its Phase I clinical trial evaluating the efficacy and safety of PRV-002 (https://ibn.fm/2zS5F), the company’s novel drug candidate for treating concussion.

For Odyssey, a medical company focused on creating and commercializing unique, life-improving medical products, concussion – a mild traumatic brain injury (“mTBI”) caused by a jolt, bump, or blow to the head – represented an unmet clinical need. Despite its high prevalence in the U.S., with figures showing that as many as five million concussions occur annually (https://ibn.fm/qV6NY), the condition does not have a Food and Drug Administration (“FDA”)-approved drug. 

“Odyssey’s primary drug candidate is being developed as the first treatment for concussion,” a white paper posted on the company’s website reads (https://ibn.fm/GCgFp). “The drug candidate, PRV-002, is a novel neurosteroid that easily crosses the blood-brain barrier.”

The company completed the GMP synthesis of PRV-002 and all pre-clinical efficacy studies, which showed that the drug candidate “improves behavioral (working memory, motor performance, and anxiety levels) and molecular (inflammation, oxidative stress, and swelling) outcomes following brain trauma through an amplified neuroprotective gene response internal to cells in the brain,” and has now embarked on human trials. As part of the ongoing human study, grouped into SAD and MAD portions, Odyssey is administering PRV-002 to healthy human subjects. 

The successfully completed SAD arm of the Phase I trial involving three cohorts showed the drug was safe and well tolerated, influencing expectations and confidence that PRV-002 will continue to show safety during the MAD portion of the trial. 

“We have unanimously approved the start of MAD Cohort I,” commented Dallas Hack, MD, member of the Safety Review Committee, following the completion of Phase I SAD trial (https://ibn.fm/WrJDo). “I am especially excited to see the overall low levels of PRV-002 in the blood supporting the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case, not only can the targeted effects of the drug be more efficacious, the drug will likely have less potential side effects.”

And with Odyssey having recently announced positive results from Cohort I of the MAD arm of the study, Odyssey’s Phase I clinical trial appears to be ticking all the expected checkboxes. According to the company, the MAD Cohort I (eight healthy subjects) received one low dose of intranasal PRV-002 for five consecutive days, followed by evaluations that showed the drug was safe and well tolerated. 

“I am very happy to see these positive safety results when dosing for multiple days. PRV-002 appears to be well-tolerated when given intranasally. If PRV-002 is found to be efficacious for concussed patients in the Phase II/III trials, I believe that intranasal brain-targeting will be the key to its success. So far, the intranasal drug/device combination has functioned nicely and has been well-tolerated in the clinical setting,” said Dr. Jacob VanLandingham, the head of drug development for the PRV-002 concussion treatment at Odyssey Health, of the recent positive results.

The Phase I MAD clinical trial will involve 16 healthy subjects, with the subsequent cohorts receiving a higher dose than Cohort I. The company expects to report additional MAD results as they become available.

For more information, visit the company’s website at www.OdysseyHealthInc.com.

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).